These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25421752)

  • 41. New PFO device for closure of patent foramen ovale in patients who had a history of cryptogenic stroke; a report of 14 cases.
    Srimahachota S; Sansanayudh N; Lertsuwunseri V; Cholteesupachai J; Lertsapcharoen P
    J Med Assoc Thai; 2015 Jan; 98 Suppl 1():S107-10. PubMed ID: 25764621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism.
    Wahl A; Praz F; Tai T; Findling O; Walpoth N; Nedeltchev K; Schwerzmann M; Windecker S; Mattle HP; Meier B
    Heart; 2010 Jun; 96(12):967-73. PubMed ID: 20538672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Feasibility of patent foramen ovale closure with no-device left behind: first-in-man percutaneous suture closure.
    Ruiz CE; Kipshidze N; Chiam PT; Gogorishvili I
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):921-6. PubMed ID: 18412251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atrial septal defect and patent foramen ovale: early and long-term effects on endothelial function after percutaneous occlusion procedure.
    Scicchitano P; Gesualdo M; Cortese F; Acquaviva T; de Cillis E; Bortone AS; Ciccone MM
    Heart Vessels; 2019 Sep; 34(9):1499-1508. PubMed ID: 30895384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Percutaneous patent foramen ovale closure: outcomes with the Premere and Amplatzer devices.
    Bissessor N; Wong AW; Hourigan LA; Jayasinghe RS; Scalia GS; Burstow DJ; Griffiths LR; Savage M; Walters DL
    Cardiovasc Revasc Med; 2011; 12(3):164-169. PubMed ID: 21640934
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transcatheter interatrial septal defect closure in a large cohort: midterm follow-up results.
    Aytemir K; Oto A; Özkutlu S; Canpolat U; Kaya EB; Yorgun H; Şahiner L; Sunman H; Ateş AH; Kabakçı G
    Congenit Heart Dis; 2013; 8(5):418-27. PubMed ID: 23601507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Occlutech percutaneous patent foramen ovale closure: Safety and efficacy registry (OPPOSE).
    Hildick-Smith D; Williams T; MacCarthy P; Melikian N; Monaghan M; Spence M; MacDonald ST; Duke A; Kovac J; McGregor A; Hilling-Smith R; Gomes A; Thomson C; Mullen M; Morrison L
    Int J Cardiol; 2017 Oct; 245():99-104. PubMed ID: 28778466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Using the GORE® Septal Occluder (GSO) in challenging patent foramen ovale (PFO) anatomies.
    Geis NA; Pleger ST; Katus HA; Hardt SE
    J Interv Cardiol; 2015 Apr; 28(2):190-7. PubMed ID: 25728716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Follow-up of residual shunt after patent foramen ovale closure.
    Orzan F; Liboni W; Bonzano A; Molinari F; Ribezzo M; Rebaudengo N; Grippi G; Negri E
    Acta Neurol Scand; 2010 Oct; 122(4):257-61. PubMed ID: 19951266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implantation of a second closure device in patients with residual shunt after percutaneous closure of patent foramen ovale.
    Schwerzmann M; Windecker S; Wahl A; Nedeltchev K; Mattle HP; Seiler C; Meier B
    Catheter Cardiovasc Interv; 2004 Dec; 63(4):490-5. PubMed ID: 15558761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patent foramen ovale closure with the SeptRx device initial experience with the first "In-Tunnel" device.
    Zimmermann WJ; Heinisch C; Majunke N; Staubach S; Russell S; Wunderlich N; Sievert H
    JACC Cardiovasc Interv; 2010 Sep; 3(9):963-7. PubMed ID: 20850097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Propensity-Score Matched Comparison of the Cera PFO Occluder With the Amplatzer PFO Occluder for Percutaneous Closure of Patent Foramen Ovale Without Echocardiographic Guidance.
    Ulmi M; Praz F; Siontis GCM; Wahl A; Windecker S; Mattle HP; Meier B
    J Invasive Cardiol; 2017 Aug; 29(8):280-284. PubMed ID: 28570259
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of transcatheter closure of patent foramen ovale in the evolution of migraine and role of residual shunt.
    Biasco L; Infantino V; Orzan F; Vicentini S; Rovera C; Longo G; Chinaglia A; Belli R; Allais G; Gaita F
    J Cardiol; 2014 Nov; 64(5):390-4. PubMed ID: 24713153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transesophageal echocardiography-guided versus fluoroscopy-guided patent foramen ovale closure: A single center registry.
    Achim A; Hochegger P; Kanoun Schnur SS; Moser L; Stark C; Pranevičius R; Prunea D; Schmidt A; Ablasser K; Verheyen N; Kolesnik E; Maier R; Luha O; Ruzsa Z; Zirlik A; Toth GG
    Echocardiography; 2023 Jul; 40(7):657-663. PubMed ID: 37248818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficiency of transcatheter patent foramen ovale closure in children after paradoxical embolism events.
    Wawrzyńczyk M; Gałeczka M; Karwot B; Knop M; Białkowski J
    Kardiol Pol; 2016; 74(4):385-9. PubMed ID: 26412471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determinants and clinical significance of persistent residual shunting in patients with percutaneous patent foramen ovale closure devices.
    Shafi NA; McKay RG; Kiernan FJ; Silverman IE; Ahlquist M; Silverman DI
    Int J Cardiol; 2009 Nov; 137(3):314-6. PubMed ID: 19616327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Percutaneous closure of the patent foramen ovale using the HELEX® Septal Occluder: acute and long-term results in 405 patients.
    Heinisch C; Bertog S; Wunderlich N; Majunke N; Baranowski A; Leetz M; Fischer E; Staubach S; Zimmermann W; Hofmann I; Sievert H
    EuroIntervention; 2012 Oct; 8(6):717-23. PubMed ID: 23086790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Angiography vs transesophageal echocardiography-guided patent foramen ovale closure: A propensity score matched analysis of a two-center registry.
    Scacciatella P; Meynet I; Giorgi M; Biava LM; Matranga I; Biasco L; Omedè P; Orzan F; Gaita F
    Echocardiography; 2018 Jun; 35(6):834-840. PubMed ID: 29457261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size.
    Wahl A; Tai T; Praz F; Schwerzmann M; Seiler C; Nedeltchev K; Windecker S; Mattle HP; Meier B
    JACC Cardiovasc Interv; 2009 Feb; 2(2):116-23. PubMed ID: 19463412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.